A Phase 1b/2a Trial Adding X4P-001 in Patients Receiving Nivolumab for Treatment of Advanced Clear Cell Renal Cell Carcinoma
Phase of Trial: Phase I/II
Latest Information Update: 27 Jul 2017
At a glance
- Drugs Nivolumab (Primary) ; X4P 001 (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- Sponsors X4 Pharmaceuticals
- 26 Jan 2017 According to a X4 Pharmaceuticals media release, first patient has been dosed in this study.
- 02 Nov 2016 Status changed from not yet recruiting to recruiting.
- 13 Oct 2016 New trial record